The Early Valve Replacement in Severe ASYmptomatic Aortic Stenosis Study

NCT ID: NCT04204915

Last Updated: 2025-09-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

2844 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-03-10

Study Completion Date

2031-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aortic stenosis (AS) affects approximately 5% of individuals \>65 years old, with \~3% of people \>75 years having moderate to severe disease. The prevalence of AS is rising rapidly due to an ageing population and is projected to double in the next two decades. Increasingly clinicians face the dilemma of how to best manage this growing population of mainly elderly patients, many of whom are asymptomatic but have been identified as having severe AS, often as an incidental finding. Reduced aortic valve opening progresses over decades without any apparent symptoms because the heart compensates for the AS. Ultimately, compensatory mechanisms fail resulting in angina, syncope or heart failure. If these symptomatic patients with severe AS remain untreated, they have a dire prognosis. In this situation the only effective treatment is AVR, either surgically or using TAVI. Conversely, conventional teaching and clinical practice in cardiology has been that, in the absence of symptoms, the prognosis is usually excellent and, except in a few very specific circumstances, conservative management and regular review (expectant management) is recommended. This advice is reflected in current international guidelines but is based largely on historical precedent. There has never been a randomised controlled trial to address the relative benefits of early AVR versus expectant management in patients with severe asymptomatic AS. The relative benefits of a strategy of early AVR/TAVI versus expectant management in patients with asymptomatic severe AS are unclear. There is clinical equipoise but it remains one of the few areas of cardiovascular medicine where no randomised controlled trials (RCT) have been performed. The EASY-AS study will provide crucial data on the relative merits of these differing approaches to management, in terms of important patient orientated outcomes, conventional cardiovascular end-points and cost effectiveness.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a major pragmatic multi-centre prospective parallel group open RCT. It will be conducted in the UK, Australia and New Zealand, funding is being sought in several countries to expand recruitment internationally. The study is in 2 phases: the vanguard and main phase. Therefore the study will run an internal pilot to prove recruitment of the relevant number of participants during the initial 2 years.

The over-arching aim is to determine whether early AVR results in better clinical outcomes and cost-effectiveness than a strategy of expectant management in asymptomatic patients with severe AS.

The primary hypothesis is that early AVR or TAVI in asymptomatic patients with severe AS will result in a reduction in the composite primary outcome of cardiovascular (CV) death and hospitalisation for heart failure (HHF) when compared to the conventional approach of expectant management.

Potential participants will be identified by a member of the clinical care team following diagnosis with severe AS. Participants will be screened for eligibility using pre-specified inclusion/exclusion criteria. Eligible participants will be provided with a written version of the participant information sheet detailing the exact nature of the study, what it will involve for the participant and any risks involved with taking part. Participants will be given at least 24 hours to consider the information and decide whether or not to take part. The study will randomise up to 2844 patients with severe asymptomatic AS to either allocated expectant management OR aortic valve replacement. Participants randomised to AVR will be placed on a waiting list with the aim that surgery will be performed within 3 months, dependent on local hospitals' waiting lists. Participants randomised to AVR will undergo routine tests/procedures which may include coronary angiography. If the outcome of the coronary angiography reveals coronary heart disease, the decision to perform CABG or PCI will be made by the responsible cardiac surgeon and cardiologist, in consultation with the patient. All analyses will be undertaken using the principles of intention-to-treat with participants analysed in the group they were randomised regardless of treatment received.

EASY-AS is collaborating with the EVoLVeD study (Early Valve Replacement guided by Biomarkers of Left Ventricular Decompensation in Asymptomatic Patients with Severe Aortic Stenosis, Clinical Trials.gov NCT03094143). In centres where both EASY-AS and EVoLVeD are running, participants in EASY-AS will be offered the opportunity to take part in EVoLVeD.

Funding has been granted by the British Heart Foundation (UK), Medical Research Future Fund (Aus) and Heart Foundation (NZ). The UK sponsor is the University of Leicester. Additional support and resources for the study will be provided by the participating Trusts and their corresponding Clinical Research Networks in the UK. The central co-ordination centre is the University of Leicester Clinical Trials Unit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A: Aortic valve replacement

Participants randomised to AVR will be investigated and managed according to local protocols and standard practice. Participants will be placed on the waiting list with the aim that surgery will be performed within 3 months, dependent on local hospitals' waiting lists.

Group Type ACTIVE_COMPARATOR

Aortic valve replacement

Intervention Type PROCEDURE

Participants will be assessed by a member of the surgical team performing aortic valve replacement (AVR), and by any other relevant medical professionals identified by the doctors overseeing their care in hospital. When deemed ready for AVR, a member of the surgical team will ask for consent to proceed with the AVR. They will discuss the surgical procedure, covering information on the basic technical procedure, risks and expected recovery time.

Group B: Expectant management

Participants randomised to expectant management will continue to have regular monitoring of their condition in line with the procedures and standard practices of their hospital.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aortic valve replacement

Participants will be assessed by a member of the surgical team performing aortic valve replacement (AVR), and by any other relevant medical professionals identified by the doctors overseeing their care in hospital. When deemed ready for AVR, a member of the surgical team will ask for consent to proceed with the AVR. They will discuss the surgical procedure, covering information on the basic technical procedure, risks and expected recovery time.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age \>18 years
2. Patient has severe asymptomatic AS, in line with current international guidelines, defined as either:

1. Peak velocity ≥4m/s OR mean pressure gradient ≥40mmHg WITH aortic valve area ≤1.0cm2 OR ≤0.6cm2/m2 body surface area OR
2. Peak velocity ≥4m/s OR mean pressure gradient ≥40mmHg WITH aortic valve area \>1.0 - ≤1.2cm2 OR \>0.6 - ≤0.7cm2/m2 body surface area AND high sex specific calcium score\* OR
3. Peak Velocity ≥3.5m/s - 3.9m/s AND mean pressure gradient \<40 mmHg WITH aortic valve area ≤1.0cm2 OR ≤0.6cm2/m2 body surface area AND high sex specific calcium score\* \*Sex specific high calcium scores (Agatston units): \>1200 females; \>2000 males
3. The responsible clinician feels that either ongoing surveillance or early AVR are appropriate.
4. Regarded by the treating cardiologist to be suitable for AVR (surgical or TAVI) with an acceptable risk
5. Willing to provide informed consent and be randomised to early AVR or expectant management
6. An ability to understand one of the written languages that the study has provided written and visual materials in, or the availability of a translator to explain the study documentation

Exclusion Criteria

7. Symptoms related to AS
8. Additional severe valvular heart disease
9. Other cardiac surgery planned pre-randomisation (eg CABG)
10. Left ventricular systolic dysfunction (LVEF \<50%)
11. Pregnancy
12. Co-morbid condition that, in the opinion of the treating cardiologist, limits life expectancy to \<2 years
13. Patient has previously undergone AVR or TAVI with restenosis
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Auckland, New Zealand

OTHER

Sponsor Role collaborator

University Hospitals, Leicester

OTHER

Sponsor Role collaborator

The University of Western Australia

OTHER

Sponsor Role collaborator

University of Leicester

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gerry McCann, Prof

Role: PRINCIPAL_INVESTIGATOR

University of Leicester

Graham Hillis, Prof

Role: PRINCIPAL_INVESTIGATOR

The University of Western Australia

Ralph Stewart, Prof

Role: PRINCIPAL_INVESTIGATOR

University of Aukland

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Canberra Hospital

Garran, Australian Capital Territory, Australia

Site Status RECRUITING

Liverpool Hospital

Liverpool, New South Wales, Australia

Site Status RECRUITING

Royal North Shore Hospital

St Leonards, New South Wales, Australia

Site Status RECRUITING

Westmead Hospital

Westmead, New South Wales, Australia

Site Status RECRUITING

Wollongong Hospital

Wollongong, New South Wales, Australia

Site Status RECRUITING

Prince Charles Hospital

Chermside, Queensland, Australia

Site Status RECRUITING

Townsville Hospital

Douglas, Queensland, Australia

Site Status RECRUITING

The Gold Coast Hospital

Southport, Queensland, Australia

Site Status RECRUITING

Royal Adelaide Hospital

Adelaide, South Australia, Australia

Site Status RECRUITING

Flinders Medical Centre

Adelaide, South Australia, Australia

Site Status RECRUITING

Monash Health

Clayton, Victoria, Australia

Site Status RECRUITING

University Hospital Geelong

Geelong, Victoria, Australia

Site Status RECRUITING

Fiona Stanley Hospital

Perth, Western Australia, Australia

Site Status RECRUITING

Royal Perth Hospital

Perth, Western Australia, Australia

Site Status RECRUITING

Lyell McEwin Hospital

Elizabeth Vale, , Australia

Site Status RECRUITING

Northern Hospital

Epping, , Australia

Site Status RECRUITING

Royal Hobart Hospital

Hobart, , Australia

Site Status RECRUITING

Nepean Hospital

Kingswood, , Australia

Site Status RECRUITING

John Hunter Hospital

New Lambton Heights, , Australia

Site Status RECRUITING

Royal Darwin Hospital

Tiwi, , Australia

Site Status RECRUITING

Sint-Jan Hospital

Bruges, , Belgium

Site Status RECRUITING

Ziekenhuis Oost-Limburg

Genk, , Belgium

Site Status RECRUITING

University Hospital of Brussels

Jette, , Belgium

Site Status RECRUITING

Frisius Medical Center

Leeuwarden, , Netherlands

Site Status RECRUITING

Radboud University Medical Center

Nijmegen, , Netherlands

Site Status RECRUITING

Auckland City Hospital

Auckland, , New Zealand

Site Status RECRUITING

Christchurch Hospital

Christchurch, , New Zealand

Site Status RECRUITING

Dunedin Hospital

Dunedin, , New Zealand

Site Status RECRUITING

Institute of Cardiovascular Diseases

Kamenitz, , Serbia

Site Status RECRUITING

Hospital Germans Trias

Barcelona, , Spain

Site Status RECRUITING

University Hospital of Navarra

Pamplona, , Spain

Site Status RECRUITING

University Hospital of North Durham

Durham, County Durham, United Kingdom

Site Status RECRUITING

Glan Clwyd Hospital

Bodelwyddan, Denbighshire, United Kingdom

Site Status RECRUITING

Dorset County Hospital

Dorchester, Dorset, United Kingdom

Site Status WITHDRAWN

Basingstoke and North Hampshire Hospital

Basingstoke, Hampshire, United Kingdom

Site Status RECRUITING

University Hospitals Leicester, Glenfield

Leicester, Leicestershire, United Kingdom

Site Status RECRUITING

Royal Liverpool Hospital

Liverpool, Merseyside, United Kingdom

Site Status RECRUITING

Norfolk and Norwich University Hospital

Norwich, Norfolk, United Kingdom

Site Status RECRUITING

Scunthorpe General Hospital

Scunthorpe, North Lincolnshire, United Kingdom

Site Status RECRUITING

Kettering General Hospital

Kettering, Northamptonshire, United Kingdom

Site Status RECRUITING

Wansbeck General Hospital

Ashington, Northumberland, United Kingdom

Site Status RECRUITING

Raigmore Hospital

Inverness, Scotland, United Kingdom

Site Status RECRUITING

Musgrove Park Hospital

Taunton, Somerset, United Kingdom

Site Status RECRUITING

Morriston Hospital

Swansea, Wales, United Kingdom

Site Status RECRUITING

Russells Hall Hospital

Dudley, West Midlands, United Kingdom

Site Status RECRUITING

George Eliot Hospital

Nuneaton, West Midlands, United Kingdom

Site Status RECRUITING

Walsall Manor Hospital

Walsall, West Midlands, United Kingdom

Site Status RECRUITING

Sandwell General Hospital

West Bromwich, West Midlands, United Kingdom

Site Status RECRUITING

Wycombe Hospital

High Wycombe, Wycombe, United Kingdom

Site Status RECRUITING

Aberdeen Royal Infirmary

Aberdeen, , United Kingdom

Site Status RECRUITING

Aintree University Hospital

Aintree, , United Kingdom

Site Status RECRUITING

University Hospital Ayr

Ayr, , United Kingdom

Site Status RECRUITING

Barnsley Hospital NHS Foundation Trust

Barnsley, , United Kingdom

Site Status RECRUITING

Basildon University Hospital

Basildon, , United Kingdom

Site Status RECRUITING

Queen Elizabeth Hospital

Birmingham, , United Kingdom

Site Status RECRUITING

Blackpool Victoria Hospital

Blackpool, , United Kingdom

Site Status RECRUITING

Royal Sussex County Hospital

Brighton, , United Kingdom

Site Status RECRUITING

North Cumbria Integrated Care

Carlisle, , United Kingdom

Site Status RECRUITING

Chesterfield Royal Hospital

Chesterfield, , United Kingdom

Site Status RECRUITING

University Hospital Coventry &amp; Warwickshire

Coventry, , United Kingdom

Site Status RECRUITING

County Durham and Darlington NHS Foundation Trust

Darlington, , United Kingdom

Site Status RECRUITING

Doncaster Royal Infirmary

Doncaster, , United Kingdom

Site Status RECRUITING

Ninewells Hospital

Dundee, , United Kingdom

Site Status RECRUITING

The Royal Infirmary of Edinburgh

Edinburgh, , United Kingdom

Site Status RECRUITING

Royal Devon & Exeter Hospital

Exeter, , United Kingdom

Site Status RECRUITING

Gateshead Health NHS Foundation Trust

Gateshead, , United Kingdom

Site Status RECRUITING

Golden Jubilee National Hospital

Glasgow, , United Kingdom

Site Status RECRUITING

Glasgow Royal Infirmary

Glasgow, , United Kingdom

Site Status RECRUITING

Queen Elizabeth University Hospital

Glasgow, , United Kingdom

Site Status RECRUITING

Gloucestershire Hospitals NHS Foundation

Gloucester, , United Kingdom

Site Status RECRUITING

Huddersfield Royal Infirmary

Huddersfield, , United Kingdom

Site Status RECRUITING

West Middlesex University Hospital

Isleworth, , United Kingdom

Site Status RECRUITING

Airedale General Hospital

Keighley, , United Kingdom

Site Status RECRUITING

University Hospital Crosshouse

Kilmarnock, , United Kingdom

Site Status RECRUITING

Leeds General Infirmary

Leeds, , United Kingdom

Site Status RECRUITING

Lincoln County Hospital

Lincoln, , United Kingdom

Site Status RECRUITING

Liverpool Heart and Chest Hospital

Liverpool, , United Kingdom

Site Status RECRUITING

Royal Liverpool Hospital

Liverpool, , United Kingdom

Site Status NOT_YET_RECRUITING

St Bartholomew's Hospital

London, , United Kingdom

Site Status RECRUITING

St Thomas' Hospital

London, , United Kingdom

Site Status RECRUITING

University Hospital Lewisham

London, , United Kingdom

Site Status RECRUITING

Chelsea and Westminster Hospital

London, , United Kingdom

Site Status RECRUITING

St George's Hospital

London, , United Kingdom

Site Status RECRUITING

Cleveland Clinic London Hospital

London, , United Kingdom

Site Status RECRUITING

Imperial College Healthcare NHS Trust

London, , United Kingdom

Site Status RECRUITING

Maidstone & Tunbridge Wells Hospital

Maidstone, , United Kingdom

Site Status RECRUITING

Wythenshawe Hospital

Manchester, , United Kingdom

Site Status RECRUITING

North Manchester General Hospital

Manchester, , United Kingdom

Site Status RECRUITING

The James Cook University Hospital

Middlesbrough, , United Kingdom

Site Status RECRUITING

Freeman Hospital

Newcastle upon Tyne, , United Kingdom

Site Status RECRUITING

Kings Mill Hospital

Nottingham, , United Kingdom

Site Status RECRUITING

Queens Medical Centre

Nottingham, , United Kingdom

Site Status RECRUITING

Royal Alexandra Hospital

Paisley, , United Kingdom

Site Status RECRUITING

Derriford Hospital

Plymouth, , United Kingdom

Site Status RECRUITING

Poole Hospital

Poole, , United Kingdom

Site Status RECRUITING

Queen Alexandra Hospital

Portsmouth, , United Kingdom

Site Status RECRUITING

Northern General Hospital

Sheffield, , United Kingdom

Site Status RECRUITING

Southampton General Hospital

Southampton, , United Kingdom

Site Status RECRUITING

Forth Valley Royal Hospital

Stirling, , United Kingdom

Site Status RECRUITING

Stepping Hill Hospital

Stockport, , United Kingdom

Site Status RECRUITING

North Tees and Hartlepool NHS Foundation Trust

Stockton-on-Tees, , United Kingdom

Site Status RECRUITING

South Tyneside and Sunderland NHS Foundation Trust

Sunderland, , United Kingdom

Site Status RECRUITING

Torbay Hospital

Torquay, , United Kingdom

Site Status RECRUITING

Royal Cornwall Hospital

Truro, , United Kingdom

Site Status RECRUITING

Pinderfields Hospital

Wakefield, , United Kingdom

Site Status RECRUITING

South Warwickshire University NHS Foundation Trust

Warwick, , United Kingdom

Site Status RECRUITING

Watford General Hospital

Watford, , United Kingdom

Site Status RECRUITING

New Cross Hospital

Wolverhampton, , United Kingdom

Site Status RECRUITING

Worcester Acute Hospitals NHS FT

Worcester, , United Kingdom

Site Status RECRUITING

Yeovil District Hospital

Yeovil, , United Kingdom

Site Status WITHDRAWN

Countries

Review the countries where the study has at least one active or historical site.

Australia Belgium Netherlands New Zealand Serbia Spain United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Carla Richardson

Role: CONTACT

+44 0116-229-7936 ext. 7936

Michael Walters

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Professor Walter Abhayaratna

Role: primary

Professor Dominic Leung

Role: primary

Professor Ravinay Bhindi

Role: primary

Dr Dylan Wynne

Role: primary

Dr Edward Danson

Role: primary

Dale Murdoch

Role: primary

Dr Lim Eng

Role: primary

Dr Kuljit Singh

Role: primary

Dr Jerrett Lau

Role: primary

Professor Joseph Selvanayagam

Role: primary

Professor Julian Smith

Role: primary

A/Professor John Amerena

Role: primary

Dr Gerald Yong

Role: primary

Professor Graham Hillis

Role: primary

Dr Luan Huynh

Role: primary

Dr Chiew Wong

Role: primary

Dr Ashutosh Hardikar

Role: primary

Professor Kaz Negishi

Role: primary

A/Professor Aaron Sverdlov

Role: primary

Dr Hussam Tayeb

Role: primary

Dr Philippe Debonnaire

Role: primary

Dr Philippe Bertrand

Role: primary

Dr Xavier Galloo

Role: primary

Olga Bondarenko

Role: primary

Saloua ElMessaoudi

Role: primary

Professor Ralph Stewart

Role: primary

Dr Philip Adamson

Role: primary

Dr Sean Coffey

Role: primary

Lazar Velicki

Role: primary

Dr Victoria Delgado

Role: primary

Rafael Sadaba

Role: primary

Darragh Twomey

Role: primary

Satheesh Nair

Role: primary

Dr Jason Glover

Role: primary

Dr Anvesha Singh

Role: primary

Prathap Kanagala

Role: primary

Dr Vassilios Vassiliou

Role: primary

Rashed Hossain

Role: primary

Dr Kai Hogrefe

Role: primary

Dr David Ripley

Role: primary

Stephen Leslie

Role: primary

Thomas Rees

Role: primary

Alexander Chase

Role: primary

Craig Barr

Role: primary

Suresh Krishnamoorthy

Role: primary

Rumi Jaumdally

Role: primary

Abdul Maher

Role: primary

Dr Piers Clifford

Role: primary

Dr Ciprian Dospinescu

Role: primary

Mr Hussein El-Shafei

Role: backup

Dr Prathap Kanagala

Role: primary

Dr Jim McGowan

Role: primary

Deoraj Zamfar

Role: primary

Dr Jason Dungu

Role: primary

Professor Rick Steeds

Role: primary

Professor Nidal Bittar

Role: primary

Dr David Hildick-Smith

Role: primary

Dr Rhidian Shelton

Role: primary

Dr Justin Cooke

Role: primary

Dr Luke Tapp

Role: primary

Dr Jamal Khan

Role: backup

Dr Darragh Twomey

Role: primary

Dr Gillian Payne

Role: primary

Chim Lang

Role: primary

Professor Marc Dweck

Role: primary

Professor David Newby

Role: backup

Dr Andrew Ludman

Role: primary

Dr Ashfaq Mohammed

Role: primary

Dr Nawwar Al-Attar

Role: primary

Dr Stuart Watkins

Role: primary

Fraser Graham

Role: primary

Val Nikolaidou

Role: primary

Dr Hossam El Mahy

Role: primary

Dr Gajen Sunthar Kanaganayagam

Role: primary

Dr Haqeel Jamil

Role: primary

Dr Angie Ghattas

Role: primary

Professor John Greenwood

Role: primary

Dr Kelvin Lee

Role: primary

Dr Timothy Fairbairn

Role: primary

Dr Prathap Kanagala

Role: primary

Dr Michael Fisher

Role: backup

Dr Thomas Treibel

Role: primary

Professor Ronak Rajani

Role: primary

Dr Amar Singh

Role: primary

Dr Gajen Sunthar Kanaganayagam

Role: primary

Dr Sami Firoozi

Role: primary

Dr Guy Llyod

Role: primary

Professor Jamil Mayet

Role: primary

Dr Timothy Williams

Role: primary

Dr Laura Dobson

Role: primary

Dr Laura Dobson

Role: primary

Dr Ahmed Adlan

Role: backup

Dr Jeet Thambyrajah

Role: primary

Professor Vijay Kunadian

Role: primary

Dr Thandar Aye

Role: primary

Dr Michael Sosin

Role: primary

Dr Stuart Hood

Role: primary

Dr Sivasankar Sangaraju

Role: primary

Mr Sanjay Asopa

Role: backup

Dr Chris Steadman

Role: primary

Dr Peter Haworth

Role: primary

Dr Muhhammad Aetesam-ur-Rahman

Role: primary

Professor Nick Curzen

Role: primary

Mr Sunil Ohri

Role: backup

Dr Christopher Gingles

Role: primary

Dr Rosica Panayotova

Role: primary

Dr Paul Davison

Role: primary

Samuel McClure

Role: primary

Dr Usman Sheikh

Role: primary

Dr Mohammed Abubakr

Role: primary

Dr Thomas Craven

Role: primary

Dr John Fryearson

Role: primary

Dr Piyush Jain

Role: primary

Sandeep Hothi

Role: primary

Ashiq Saffy

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CS/18/7/33714

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

266292

Identifier Type: OTHER

Identifier Source: secondary_id

90865

Identifier Type: OTHER

Identifier Source: secondary_id

0700

Identifier Type: OTHER

Identifier Source: secondary_id

0700

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

EffecTAVI Registry
NCT05235555 RECRUITING